[Metastasectomy for renal cell cancer]

Area of Science:

• Oncology
• Surgical Oncology

Context:

• Metastatic renal cell cancer (mRCC) management involves multimodal therapy.
• The role of metastasectomy in mRCC is debated, with unquantifiable benefits.
• Systemic treatment and metastasectomy are used to improve mRCC prognosis.

Purpose:

• To critically review existing data on metastasectomy in mRCC.
• To evaluate the therapeutic benefit and role of metastasectomy in mRCC.

Summary:

• Metastasectomy is recommended in mRCC guidelines for patients with stable disease (≥3 months), resectable lesions, and good performance status.
• Median survival times for mRCC patients undergoing metastasectomy range from 35 to 55 months.
• Metastasectomy is an individualized approach for limited metastatic disease in mRCC, aiming to improve survival.

Impact:

• Metastasectomy can be a valuable therapeutic option for specific mRCC patients.
• Early consideration of metastasectomy may enhance survival in mRCC.
• This review provides insights into the current evidence supporting metastasectomy in mRCC.